Actively Recruiting
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
Led by Showa Inan General Hospital · Updated on 2026-05-13
300
Participants Needed
1
Research Sites
326 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.
CONDITIONS
Official Title
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients suspected of having possible ulcerative colitis or Crohn disease
You will not qualify if you...
- Other autoimmune diseases
- Acute or chronic renal failure
- Chronic heart diseases
- Liver cirrhosis
- Cancer
- Acute or chronic infections
- Ischemic colitis
- Infectious colitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Showa Inan General Hospital
Komagane, Nagano, Japan, 399-4117
Actively Recruiting
Research Team
A
Akira Horiuchi, MD
CONTACT
M
Masashi Kajiyama, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here